Bolt Biotherapeutics, Inc.
As of Oct 22, 2026, Bolt Biotherapeutics is in Stage 4, the downtrend phase, now in week 17 (since Jun 29, 2026). It closed at $4.19, 40.9% below its 52-week high and below its 200-day average, which is falling.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BOLT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BOLT among Biotechnology270th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …270 | BOLT | Stage 4 · wk 17 | 35 | +14.8% |
Bolt Biotherapeutics: quick answers
What stage is Bolt Biotherapeutics in?
As of Oct 22, 2026, Bolt Biotherapeutics (BOLT) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 29, 2026 and is in week 17. What the four stages mean
Is Bolt Biotherapeutics in an uptrend?
No. Bolt Biotherapeutics is in a Stage 4 downtrend. It trades 6.7% below its 200-day average, which is falling.
How far is Bolt Biotherapeutics from its 52-week high?
Bolt Biotherapeutics closed at $4.19 on Oct 22, 2026, 40.9% below its 52-week high of $7.09. Its 52-week low is $3.18.
How has Bolt Biotherapeutics performed over the past year?
As of Oct 22, 2026, Bolt Biotherapeutics is down 27.1% over the past year and down 27.6% so far in 2026.
Which sector and industry is Bolt Biotherapeutics in?
Bolt Biotherapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.